Cidara Eliminates 30% Of Workforce To Prioritize Clinical Development Of CD388; Stock Down
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Cidara Therapeutics Inc. (CDTX) has announced a reduction in its workforce by approximately 30% to concentrate on advancing the clinical development of CD388, the company’s innovative DFC candidate targeting influenza A and B.
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1371757399-3329dac503a74576a455122fc2b08246.jpg "<div>9 Major Medicare Changes for 2025 and How They'll Impact Your Coverage</div>")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1064987572-1a79077cb179458dbbcecc5ac1b660df.jpg "Average Equity In U.S. Homes: Overview, FAQs")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-769720227_2400a-31d6e8ea286f4dea9c854eaf18af463c.jpg "Planning for Retirement? Start With These 5 Steps")
:max_bytes(150000):strip_icc():format(jpeg)/Primary-Image-how-to-trade-0dte-options-7481013-c9af6887219942dc9c8c9374963b51ec.jpg "How to Trade 0DTE Options")